Teddy European Network of Excellence for Paediatric Clinical Research was funded in 2005 with the aim to favor the integration of the paediatric pharmacological research activities and contribute to the promotion of safe and efficacious medicines for children.
TEDDY is a Network of Excellence (NoE), strongly proactive in the promotion and implementation of adequate health policies and a social awareness on the importance of the paediatric medicines across Europe.
Today, TEDDY is an independent multidisciplinary, multinational Network composed of partners from more than 20 countries aimed at facilitating the performance of good quality paediatric studies and research.
TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency.
Any research centres and groups willing to be engaged in the development of clinical research can join the TEDDY Network. Find out more.
Latest News
SAVE THE DATE. EUCROF Webinar on “The Patient Centricity Effect – How it benefits Patients, Sites and Sponsors – Practical Cases from Paediatric Studies”. 25 February 2020
The Events&Training Working Group of EUCROF (European CRO Federation) announced the Webinar “The Patient Centricity Effect - How it benefits Patients, Sites and Sponsors – Practical Cases from Paediatric Studies” that will be
FDA Consultation: FDARA Implementation Guidance for paediatric studies of molecularly targeted oncology drugs. Amendments to Sec. 505B of the FD&C Act guidance for industry
On December 2020, the Food and Drug Administration released a draft guidance for industry entitled “FDARA Implementation Guidance for Paediatric Studies of Molecularly Targeted Oncology Drugs”. This draft guidance addresses early planning for
